November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Trials Consider Role of Immunotherapy in Breast Cancer
March 28th 2018Mixed results have occured in recent trials testing immuotherapy in patients with breast cancer. Checkpoint inhibitors have been used as monotherapy in a pair of trials, reporting lackluster overall response rates. When immunotherapy was paired with chemotherapy, on the other hand, it usually showed better results, and gave signals that immunotherapies combined with targeted agents could work better than immunotherapy alone.
Read More
New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene Fusion
March 27th 2018The new drug application for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion has been completed.
Read More
Current Research on Identifying Biomarkers in Breast Cancer
March 21st 2018Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.
Watch
Certain Breast Cancer Patients Find Endocrine Therapy Ideal
March 20th 2018Tumor reduction for patients with ER-positive breast cancer can be achieved with endocrine therapy and can possibly avoid the need for chemotherapy or even surgery in some patients. Hyman B. Muss, MD, who presented at the 2018 Miami Breast Cancer Conference, said that deciding how long to continue this therapy can be tricky, however.
Read More
Results Show HER2 Mutations Cause Endocrine Resistance in ER+ Breast Cancer
March 19th 2018Uttara Nayar, PhD, shares the findings of recent studies in patients with ER+ breast cancer. Findings have shown that acquired HER2 mutations lead to endocrine resistance, the most frequent cause of breast cancer mortality in the country.
Read More
Methods Used for Ovary Suppression in Women with Breast Cancer
March 13th 2018Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Watch
Expert Reviews Efficacy, Safety Data with Abemaciclib in Breast Cancer
March 13th 2018Abemaciclib, the only CDK4/6 inhibitor approved as a single-agent, has amassed several clinical indications for patients with metastatic breast cancer. The findings from the phase III MONARCH2 and 3 trials, as well as the phase II MONARCH1 study led to these approvals. Each trial showed improvements in progression-free survival, especially in patients with visceral disease and endocrine therapy resistance.
Read More
Study Confirms Olaparib Benefit in Advanced Breast Cancer
March 12th 2018Presented at the 2018 Miami Breast Cancer Conference, results from the phase III OlympiAD trial demonstrated improvements in progression-free survival with olaparib over treatment of physician's choice. These results were consistent regardless of the baseline tumor burden for patients with HER2-negative breast cancer with a germline <em>BRCA</em>1/2 mutation.
Read More
Frontline Palbociclib Added to Letrozole Effective in Breast Cancer Regardless of Prior Therapy
March 12th 2018The results of the phase III PALOMA-2 study were presented at the 2018 Miami Breast Cancer Conference. According to the deep analysis, the CDK 4/6 inhibitor palbociclib showed significant efficacy in combination with the aromatase inhibitor letrozole in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.
Read More
Lilly Oncology to Welcome Aboard New VP of Late Phase Development, Maura Dickler
March 10th 2018Lilly Oncology has hired Maura Dickler, MD, to serve as vice president of late phase development, beginning May 7, 2018. She will report to Levi Garraway, MD, PhD, senior vice president of global development and medical affairs of Lilly Oncology.
Read More
MONALEESA-7 Data Shows Ribociclib Active in Premenopausal Breast Cancer Subgroups
March 9th 2018According to results from the phase III MONALEESA-7 trial presented at the 2018 Miami Breast Cancer Conference, the progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer had been sustained across patient subgroups.
Read More
The Role of Biomarkers in Patients with Breast Cancer
March 8th 2018Susan M. Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the role biomarkers have in the treatment of patients with breast cancer. Identifying biomarkers in patients early on, such as knowledge of estrogen receptor status, can lead to better treatment plans, Domchek says.
Watch
The Biggest Issue with Treatment of Breast Cancer in Men
March 8th 2018Fatima Cardoso, MD, medical oncologist at the Champalimaud Clinical Centre in Portugal, explains the biggest issue in treatment of male breast cancer is due to lack of education. Male patients are most commonly diagnosed in the advanced stages because of this and are commonly given the wrong treatments, says Cardoso.
Watch